This inventor holds 5 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Universitè Laval. Active years: 2009-2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- St-Pierre lle d'Orléans, CA (2009)
- Ile d'Orléans, CA (2011)
- Ile d'Orleans, CA (2013)
Company Filing History:
Years Active: 2009-2013
Title: Innovator Spotlight: Marie-Renée Blanchet - Pioneering Nicotinic Receptor Agonists for Treating Inflammatory Diseases
Introduction: Meet the innovative mind behind groundbreaking research in the field of inflammatory disease treatment - Marie-Renée Blanchet from Ile d'Orleans, Canada. With a total of 3 patents under his belt, Blanchet has revolutionized the approach to addressing pulmonary diseases through the use of nicotinic receptor agonists.
Latest Patents: One of Blanchet's latest patents involves the use of Nicotinic Receptor Agonists for the treatment of inflammatory diseases, particularly focusing on pulmonary conditions such as asthma, interstitial pulmonary fibrosis (IPF), and bronchiolitis obliterans with organizing pneumonitis (BOOP). His research highlights the efficacy of these agonists in reducing inflammation with fewer side effects compared to traditional anti-inflammatory drugs like steroids.
Career Highlights: Currently affiliated with Université Laval, Blanchet's research and patent applications have garnered significant attention in the scientific community. His dedication to finding innovative solutions for treating inflammatory diseases has positioned him as a leading figure in the field of pulmonary medicine.
Collaborations: Blanchet has collaborated closely with notable colleagues such as Yvon Cormier and Evelyne Israel-Assayag. Together, they have contributed to advancing the understanding of nicotinic receptor agonists and their potential applications in treating a range of inflammatory conditions.
Conclusion: Marie-Renée Blanchet's pioneering work in developing Nicotinic Receptor Agonists for the treatment of inflammatory diseases showcases his commitment to advancing medical interventions for pulmonary ailments. With a strong foundation in research and a dedication to improving patient outcomes, Blanchet continues to make significant contributions to the field of healthcare innovation.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile